ALSO IN THIS MONTH'S ISSUE

• How Will The CGT Manufacturing Paradigm Mature In 2022?

  As these four cell and gene execs shared their expectations for 2022 and beyond, what emerged was a benchmark for what the CGT manufacturing paradigm could realistically look like in 2022 and which in-the-works innovations will help the industry slowly but surely mature.

• The Future Of Life Sciences Manufacturing And The Supply Chain

  In this edited transcript from our August 2021 executive virtual roundtable, perspectives on life science manufacturing and the supply chain are provided by three biopharma execs.

• Thanks To COVID, Your Culture May Need An Overhaul

  This biotech fortified its culture during the pandemic by creating an employee support group, a new performance-management program, a woman-focused initiative, and programs that give days off for volunteering and provide $1200/year for personal and family development goals.

• Tackling Uncertainty In Drug R&D

  Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.